Development of an senescence-associated system diagnostic kit for cancer and stroke - SASKit

Development of an senescence-associated system diagnostic kit for cancer and stroke - SASKit - SASKit

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021184

Enrollment

150

Registered

2020-03-27

Start date

2020-05-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25 I63

Interventions

Group 1: Patients with pancreatic cancer blood sampling, grip strength measurement, quality of life questionnaire using EQ-5D-5L, ECOG PS, CSHA - CFS, interview Group 2: patients with ischemic stroke

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Newly diagnosed Adenocarcinoma of the pancreas in the advanced or metastatic stage, no previous system therapy or Ischemic stroke of the supratentorial brain region before 3-10 days (definitive cerebral infarction volume> 10 ml on MRI) or Control person who is neither brother nor sister and has an age difference of no more than 12 years.

Exclusion criteria

Exclusion criteria: - Age <18 years - previous or current medical tumor therapy - other cancer within the past 2 years - previous stroke with persistent deficit - myocardial infarction within the past 2 years - therapeutic anticoagulation, within the past 2 years up to the time of study enrollment, for a duration of more than 1 month The exclusion criteria are described in detail in our study protocol (Henze et al., BMJ open 10:e039560, 2020, PMID 33334830)

Design outcomes

Primary

Measure	Time frame
The primary objective is a combined endpoint defined as the first deterioration of one of the following: probable sarcopenia, deterioration of ECOG PS or mRS (respectively), deterioration of quality of life evaluated by EQ-5D-L. It is described in detail in our study protocol (Henze et al., BMJ Open 10:e039560, 2020, PMID 33334830).	—

Secondary

Measure	Time frame
Secondary objectives are: new vascular event, new cancer, probable sarcopenia, cognitive decline, frailty (CSHA-CFS), all cause mortality. The secondary objectives are described in detail in our study protocol (Henze et al., BMJ Open 10:e039560, 2020, PMID 33334830)	—

Countries

Germany

Contacts

Public ContactLarissa Henze

Klinik III (Hämatologie, Onkologie, Palliativmedizin) Zentrum für Innere Medizin Universitätsmedizin Rostock

klinischestudien@med.uni-rostock.de0381 494 7326

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 17, 2026